Partner Keryx to present Phase 2 data on perifosine for multiple cancers
QUEBEC CITY, May 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108, in prostate cancer, will be presented as a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 through June 2, 2009 at the Orange County Convention Center in Orlando, Florida.
Results presented are important for the expansion of potential indications for AEZS-108. While clinical investigations so far focused on gynaecological indications, the new results show continued expression of Luteinizing Hormone Releasing Hormone (LHRH) receptors in prostate cancer specimens after prolonged use of LHRH agonists; these data provide further support to the investigation of the drug in hormone-refractory prostate cancer, a major genitourinary cancer indication in male patients.
Abstract selected for presentation is as follows:
Sunday, May 31, 2009:
# 5103: Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists
Lead Author: Stephen Liu, MD
Poster Session: 2 pm - 6 pm (Level 2, West Hall C)
Additionally, AEterna Zentaris' partner, Keryx Biopharmaceuticals, announced yesterday that it will present four posters on the Akt-inhibitor compound, perifosine, during the ASCO meeting. Keryx is currently developing perifosine in multiple Phase 2 trials for various types of cancer. All of the clinical data
|SOURCE AETERNA ZENTARIS INC.|
Copyright©2009 PR Newswire.
All rights reserved